ARTICLE SUMMARY:
Guardant's huge ambition to build a liquid biopsy business in cancer diagnostics is highlighted by its recent milestones in technically challenging indications like recurrence monitoring and earlier disease detection.
This much is certain: liquid biopsy technologies, not too long ago viewed as an aspirational achievement for select subsets of disease, are rapidly impacting clinical care in already diagnosed, advanced cancer patients. This excitement is reflected in investor interest: diagnostic test manufacturers, diagnostic testing services, and that new breed, precision medicine companies, overall outperformed the market last year, returning an average 41%.
